We are live on ! Find out more
RPTX

Repare Therapeutics

Delisted

RPTX was delisted on the 27th of January, 2026.

67 hedge funds and large institutions have $689M invested in Repare Therapeutics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 16

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

5.69% more ownership

Funds ownership: 72.63%78.31% (+5.7%)

2% more funds holding

Funds holding: 6667 (+1)

3% less capital invested

Capital invested by funds: $708M → $689M (-$18.2M)

7% less call options, than puts

Call options by funds: $207K | Put options by funds: $223K

Holders
67
Holders Change
+1
Holders Change %
+1.52%
% of All Funds
1.03%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.08%
New
11
Increased
29
Reduced
16
Closed
10
Calls
$207K
Puts
$223K
Net Calls
-$16K
Net Calls Change
-$1.32M
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$102M +$26.8M +1,136,363 +31%
O
2
OrbiMed
New York
$70.1M
Fidelity Investments
3
Fidelity Investments
Massachusetts
$63.7M +$5.6M +237,537 +9%
AIM
4
ARK Investment Management
Florida
$62.9M +$332K +14,097 +0.5%
RG
5
Redmile Group
California
$58.8M +$5.22M +221,800 +9%
MAM
6
MPM Asset Management
Massachusetts
$47.3M
CA
7
CHI Advisors
New York
$46.7M -$484K -20,527 -0.9%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$45.7M +$5.91M +250,849 +13%
DTC
9
Deep Track Capital
Connecticut
$44.3M +$49.5M +2,100,000 New
LGM
10
Logos Global Management
California
$35.9M +$39.6M +1,680,000 +8,400%
MB
11
MPM BioImpact
Massachusetts
$34.6M
AG
12
Artal Group
Luxembourg
$14.8M +$3.53M +150,000 +27%
BlackRock
13
BlackRock
New York
$9.67M +$791K +33,594 +8%
Millennium Management
14
Millennium Management
New York
$6.98M +$3.75M +159,365 +93%
AAA
15
Affinity Asset Advisors
New York
$5.73M +$6.4M +271,778 New
SAM
16
Sectoral Asset Management
Quebec, Canada
$4.36M -$7.3M -309,700 -60%
Norges Bank
17
Norges Bank
Norway
$3.94M +$4.4M +186,800 New
UBS AM
18
UBS AM
Illinois
$3.32M -$68.2K -2,895 -2%
Bank of Montreal
19
Bank of Montreal
Ontario, Canada
$3.04M -$346K -14,682 -10%
Franklin Resources
20
Franklin Resources
California
$2.82M -$3.88M -164,836 -55%
Ensign Peak Advisors
21
Ensign Peak Advisors
Utah
$1.95M +$1.72M +72,924 +376%
Renaissance Technologies
22
Renaissance Technologies
New York
$1.83M +$1.65M +69,900 +416%
TD Asset Management
23
TD Asset Management
Ontario, Canada
$1.43M +$540K +22,928 +51%
Citadel Advisors
24
Citadel Advisors
Florida
$1.36M -$33.8K -1,436 -2%
Vanguard Group
25
Vanguard Group
Pennsylvania
$1.35M +$685K +29,065 +83%

RPTX Hedge Fund Activity: Q4 2021 in Review

67 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q4 2021, worth a combined $689M — down 2.6% from $708M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new RPTX positions and 10 closed out — a net gain of 1 holder — while 29 added to existing stakes and 16 trimmed.

The largest buyer was Logos Global Management, adding an estimated $39.6M. The largest seller was Sectoral Asset Management, cutting an estimated $7.3M.

  • 67 institutional investors held Repare Therapeutics (RPTX) as of Q4 2021, up from 66 in Q3 2021.
  • Funds reported $689M of Repare Therapeutics stock for Q4 2021, down 2.6% quarter-over-quarter.
  • 11 funds opened new Repare Therapeutics positions in Q4 2021 and 10 closed out, a net change of +1 holder.
  • The largest Repare Therapeutics buyer in Q4 2021 was Logos Global Management, an estimated $39.6M added.
  • The largest Repare Therapeutics seller in Q4 2021 was Sectoral Asset Management, an estimated $7.3M sold.

Based on aggregated 13F filings for Q4 2021.